Polypeptides derived from retinoic acid-related orphan receptor (ror),and their applications
CA 2446218 A1 · Owner: Wurtz, Jean-Marie · Inventors: Renaud, Jean-Paul; Greiner, Erich Friedrich; Schuele, Roland
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to polypeptides derived from the retinoic acid-related orphan receptor (ROR) in mammals, characterized in that they are delimited in their N-terminal extremity by an amino-acid located between positions 1 to 209, and in their C-terminal extremity by an amino-acid located between positions 450 to 452 of the rat ROR.szlig. .alpha. or .gamma. or by an amino-acid located at corresponding positions in nuclear receptor ROR of other subtypes than .alpha. .beta. and .gamma. and/or of the other mammals. The invention also relates to the use of these polypeptides or of the molecular , complexes or the crystals containing them for carrying out: -a process for , the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 7, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 7, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 7, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.